American Century Companies Inc. Decreases Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

American Century Companies Inc. decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 9.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,921,397 shares of the medical equipment provider's stock after selling 621,555 shares during the quarter. Zimmer Biomet makes up 0.4% of American Century Companies Inc.'s investment portfolio, making the stock its 28th largest position. American Century Companies Inc. owned approximately 2.97% of Zimmer Biomet worth $625,477,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in ZBH. Stonebridge Financial Group LLC bought a new position in Zimmer Biomet in the 4th quarter worth about $25,000. Dunhill Financial LLC lifted its holdings in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock worth $26,000 after buying an additional 218 shares in the last quarter. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet in the third quarter valued at approximately $35,000. Kentucky Trust Co purchased a new position in Zimmer Biomet during the fourth quarter valued at approximately $39,000. Finally, OFI Invest Asset Management bought a new stake in Zimmer Biomet during the 4th quarter worth approximately $40,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Up 0.2 %

Shares of ZBH stock traded up $0.22 during mid-day trading on Wednesday, reaching $110.60. 1,259,233 shares of the company's stock traded hands, compared to its average volume of 1,497,046. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company's 50-day moving average price is $106.98 and its 200-day moving average price is $106.90. The company has a market cap of $22.02 billion, a P/E ratio of 24.85, a P/E/G ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90.

Remove Ads

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the business earned $2.20 earnings per share. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ZBH shares. Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. Royal Bank of Canada dropped their price target on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. JMP Securities reiterated a "market outperform" rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Barclays cut their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $124.15.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.95% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.